Yaping Xu
12 Papers
2 Citations
Yaping Xu is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Yu Chen,Yingying Huang,Xuan Gao,Yi Li,Jing Lin,Lizhu Chen,Lianpeng Chang,Gang Chen,Yanfang Guan,Leong Kin Pan,Xuefeng Xia,Zengqing Guo,Jianji Pan,Yaping Xu,Xin Yi,Chuanben Chen +15 more
TL;DR: Findings indicate that CCND1 amplification may be a key point related to immunosuppression in TME and multiple malignancy hallmarks, and it hinders not only the natural host immune responses but also the efficacy of ICI therapy.
•Journal Article
The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.
Yan An,Yanfang Guan,Yaping Xu,Yingxin Han,Chi Wu,Chaohui Bao,Boping Zhou,Haiyan Wang,Mingxia Zhang,Weilong Liu,Lin Qiu,Ze-Guang Han,Yongsheng Chen,Xuefeng Xia,Jiayin Wang,Zhentian Liu,Wanqiu Huang,Xin Yi,Jian Huang +18 more
TL;DR: Circulating tumor DNA profiling is potentially valuable in differential diagnosis and prognostic evaluation of HCC and multiple circulating cell-free DNA parameters could be used in differentiating malignant lesions from benign lesions.
43
Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
Yidong Zhou,Yaping Xu,Yuhua Gong,Yanyan Zhang,Yaping Lu,Changjun Wang,Ru Yao,Peng Li,Yanfang Guan,Jiayin Wang,Xuefeng Xia,Ling Yang,Xin Yi,Qiang Sun +13 more
TL;DR: In this article, the authors used noninvasive circulating tumor DNA (ctDNA) to predict breast cancer recurrence and prognosis and found that ctDNA was more often detected in locally advanced/metastatic and non-luminal patients.
38
Genotyping of Circulating Tumor DNA Reveals the Clinically-actionable Mutation Landscape of Advanced Colorectal Cancer
Weiguo Cao,Yaping Xu,Lianpeng Chang,Yuhua Gong,Liren Li,Xianwei Mo,Xin Zhang,Guole Lin,Jiaolin Zhou,Dan Liu,Yuting Yi,Pingping Dai,Chenchen Zhu,Liu Tao,Yuxing Chu,Yanfang Guan,Yongsheng Chen,Jiayin Wang,Xuefeng Xia,Ling Yang,Xin Yi,Yong Cheng +21 more
TL;DR: Comprehensive ctDNA genotyping is a promising noninvasive alternative to biopsy-derived analysis for determining targeted therapy in advanced colorectal cancer and shows favorable concordance with tumor tissues in the authors' matched analysis.
PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
Jihao Zhou,Min Zuo,Lifeng Li,Fafen Li,Peng Ke,Ya-Dong Zhou,Yaping Xu,Xuan Gao,Yanfang Guan,Xuefeng Xia,Xin Yi,Xinyou Zhang,Yuhua Huang +12 more
TL;DR: A new molecular classification was developed to divide CNS DLBCL into CDP and non-CDP groups based on CD79B and PIM1 mutational status, which revealed the subcloning heterogeneity between the groups.